Rational Advisors’s Teva Pharmaceuticals TEVA Stock Holding History

Rational Advisors’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,401	Closed	-$22K	–	559
2020 Q3	$22K	Buy	2,401 +1,853	+338%	+$19.6K	0.01%	226
2020 Q2	$7K	Buy	+548	New	+$6.2K	﹤0.01%	400
2020 Q1	–	Sell	-13,108	Closed	-$128K	–	478
2019 Q4	$128K	Sell	13,108 -7,230	-36%	-$64.5K	0.06%	253
2019 Q3	$140K	Buy	20,338 +16,157	+386%	+$124K	0.05%	266
2019 Q2	$39K	Buy	4,181 +2,953	+240%	+$35.6K	0.01%	369
2019 Q1	$19K	Sell	1,228 -1,975	-62%	-$34.8K	0.01%	394
2018 Q4	$49K	Buy	+3,203	New	+$65.7K	0.02%	285
2018 Q3	–	Sell	-159	Closed	-$4K	–	565
2018 Q2	$4K	Buy	+159	New	+$3.24K	﹤0.01%	405

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $263B AUM 16.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACM

Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $16.6B AUM 68.34% 1-Year Est. Return

Rational Advisors's TEVA Position: Q4 2020 in Review

Rational Advisors sold out of Teva Pharmaceuticals (TEVA) in Q4 2020, closing a stake of 2,401 shares — an estimated $22K sold.

Rational Advisors first reported a position in TEVA in Q2 2018 and held it in 8 quarters. The position peaked at $140K in Q3 2019. 449 funds tracked by Wall St. Rank hold TEVA as of Q4 2020.

Rational Advisors reported no remaining Teva Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Rational Advisors sold 2,401 Teva Pharmaceuticals shares in Q4 2020, an estimated $22K.
Rational Advisors first reported a position in Teva Pharmaceuticals in Q2 2018 and held it in 8 quarters.
Rational Advisors's Teva Pharmaceuticals position peaked at $140K in Q3 2019.
449 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q4 2020.

Based on Rational Advisors's 13F filing for Q4 2020, filed 5 Feb 2021.